MedTrace Logo

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2014-03-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the effectiveness and acceptability of high dose MPA (20mg oral 3 times a day) for 3 days combined with an injection of DMPA 150 mg intramuscularly in the treatment of acute heavy, prolonged uterine bleeding who have been identified as being eligible for outpatient management

Conditions

  • Dysfunctional Uterine Bleeding

Interventions

DRUG

Medroxyprogesterone 17-Acetate

Medroxyprogesterone 20mg orally 3 times a day for 3 days

DRUG

medroxyprogesterone acetate

Depo Provera 150mg Intramuscular injection

Sponsors & Collaborators

  • Women's Health Care Clinic, Torrance, California

    lead OTHER

Principal Investigators

  • Anita L. Nelson, M.D. · University of California, Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-10-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01148420 on ClinicalTrials.gov